MedWellAI (MWAI)
OTHER OTC:MWAI
Want to see MWAI full AI Analyst Report?
MWAI Stock Chart & Stats
$0.72
--
Market closed
$0.72
--
Day’s Range― - ―
52-Week Range$0.21 - $0.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)4.51K
Market Cap
$1.97M
Enterprise Value$2.75M
Total Cash (Recent Filing)$223.22K
Total Debt (Recent Filing)$600.30K
Price to Earnings (P/E)―
Beta0.57
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding6,536,580
10 Day Avg. Volume2,376
30 Day Avg. Volume4,515
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.81
Price to Sales (P/S)3.42
P/FCF Ratio-2.17
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue3.99
Enterprise Value/Gross Profit4.70
Enterprise Value/Ebitda-1.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring SaaS Revenue ModelMedWellAI’s core monetization mixes subscription SaaS, implementation fees, and ongoing support, creating recurring revenue streams and customer lock-in. That structure supports predictable long-term cash inflows and higher lifetime value per customer versus one-time sales, aiding durable revenue visibility if retention holds.
Healthcare AI Product FocusOperating at the healthcare/AI intersection gives MedWellAI exposure to structural demand for clinical decision support and workflow automation. Durable adoption drivers—efficiency, outcomes, and integration needs at hospitals—support multi-year addressable market potential for its diagnostic and care-management platforms.
Expanded Preferred Stock AuthorizationThe April 2026 amendment raising Series B authorization is a structural capital-market change that improves the company’s ability to raise preferred equity. This enhances financing flexibility to fund operations or product development without immediate bank debt, a durable lever for extending the runway if executed prudently.
Bears Say
Highly Volatile And Declining RevenueA ~61% revenue drop in 2025 after prior growth signals unstable demand or contract concentration issues. Such top-line volatility undermines scale economics and makes multi-period planning and margin improvement difficult, reducing confidence in sustainable growth absent clear customer retention fixes.
Persistent Negative Cash FlowRepeated negative operating and free cash flow, including worsening free cash flow in 2025, indicate the business cannot self-fund operations. Continued cash burn increases reliance on external financing, raises dilution risk, and constrains the ability to invest in product development or sales capacity over the medium term.
Negative Shareholder Equity And Shrinking AssetsA sustained negative shareholders’ equity position and shrinking asset base are structural solvency concerns. They limit borrowing capacity, weaken creditor confidence, and elevate the likelihood of dilutive capital raises or restructuring, reducing long-term financial resilience and strategic optionality.
MedWellAI News
MWAI FAQ
What was MedWellAI’s price range in the past 12 months?
MedWellAI lowest stock price was $0.21 and its highest was $0.80 in the past 12 months.
What is MedWellAI’s market cap?
MedWellAI’s market cap is $1.97M.
When is MedWellAI’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MedWellAI’s earnings last quarter?
MedWellAI released its earnings results on Feb 18, 2025. The company reported -$0.127 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.127.
Is MedWellAI overvalued?
According to Wall Street analysts MedWellAI’s price is currently Overvalued.
Does MedWellAI pay dividends?
MedWellAI does not currently pay dividends.
What is MedWellAI’s EPS estimate?
MedWellAI’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MedWellAI have?
MedWellAI has 6,536,580 shares outstanding.
What happened to MedWellAI’s price movement after its last earnings report?
MedWellAI reported an EPS of -$0.127 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MedWellAI?
Currently, no hedge funds are holding shares in MWAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedWellAI
MedWellAI Inc., through its subsidiary, develops, acquires, operates, and invests in businesses. It provides AI-driven healthcare and wellness solutions. The company also offers a B2B e-commerce platform for distributing pharmaceutical products, particularly GLP medications for weight loss and diabetes management. In addition, it provides an AI-powered ordering system with inventory tracking, smart suggestions, and support for healthcare providers such as wellness clinics, med spas, and corporate wellness facilities. The company was formerly known as Integrated Ventures, Inc. and changed its name to MedWellAI Inc. in June 2025. The company is based in Clearwater, Florida.
Technical Analysis
Nvni Group
―
Xiao-I Corp. ADR
―
Simpple Ltd.
―
Health In Tech, Inc. Class A
―
Cloudastructure, Inc. Class A
―